Adial Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Adial Pharmaceuticals, Inc. (ADIL) reported Net Income (Loss) Available to Common Stockholders, Basic of $219.80 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-11-14.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-11-14
- Adial Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-06-30 was $219.80K.
- Adial Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-03-31 was -$2.91M.
- Adial Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$2.91M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month |
|---|---|---|
| 2023-06-30 | $219.80K 10-Q · filed 2023-11-14 | -$2.69M derived: sum of 2 quarters · filed 2023-11-14 |
| 2023-03-31 | -$2.91M 10-Q · filed 2023-05-12 | |
| 2022-03-31 | -$2.91M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |